PDS Biotech Secures $22.55M PIPE Led by Dr. Patrick Soon-Shiong, Gains Board Seats and PDS0101 Option
PDSB has more than doubled off its 52-week low of $0.195.
Summary
PDS Biotech announced a $22.55M PIPE led by Nant Capital, with Dr. Patrick Soon-Shiong joining the board and NantWorks receiving an exclusive option to license PDS0101.
Key Events · Financing and Capital Events · PDSB
-
$22.55M PIPE Financing
Initial closing of $11.55M expected September 11, 2026, with 20,875,220 shares, 20,009,736 pre-funded warrants, and 20,442,479 common warrants. A contingent $11M milestone closing is tied to FDA submission of a PDS0301 Phase 3 protocol.
-
Nant Capital Leads Investment
Nant Capital and AB Group are named purchasers. Nant gains the right to designate two board members, including Dr. Patrick Soon-Shiong, while owning 15% or more of outstanding shares.
-
PDS0101 Exclusive Option
NantWorks receives a one-year exclusive right to negotiate an exclusive license for the PDS0101 program in exchange for $25,000.
-
Warrant Terms
Common warrants have an exercise price of $0.22 per share and expire one year from issuance. Pre-funded warrants have an exercise price of $0.00033 per share.
Analysis · PDSB · Life Sciences
With only $5.6M in cash and a going concern warning, PDS Biotech has secured up to $22.55M in a PIPE led by Nant Capital. The initial $11.55M closing is expected September 11, 2026, with a contingent $11M milestone closing tied to FDA submission of a PDS0301 Phase 3 protocol. Nant gains two board seats, including Dr. Patrick Soon-Shiong, and a one-year exclusive option to license PDS0101. This financing is critical for survival and extends the cash runway, but the terms include significant dilution and strategic concessions.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.7% of the 583 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PDSB was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.20 to $1.55. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.